Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 65 and up

Extended-release tacrolimus to improve thinking and memory in older kidney transplant recipients

Official title: Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients

Run by Massachusetts General Hospital · NCT06751992 · Data updated 2026-11-12

This will try switching older kidney transplant recipients from immediate-release tacrolimus to an extended-release formulation to see if it improves thinking, memory, or other cognitive symptoms.

Quick facts

PhasePhase 4
Study typeInterventional
Ages65 Years and up
SexAll
Enrollment92 (estimated)
SponsorMassachusetts General Hospital
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedMarch 17, 2026
Main results expectedMay 1, 2027
Study endsOctober 1, 2027
Registry record updatedMay 28, 2026
Trial IDNCT06751992 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are older kidney transplant recipients at least one year after transplant who are on stable immediate-release tacrolimus with therapeutic troughs, have stable kidney function, receive care at MGH, and speak English or Spanish.

Probably not a fit

Patients with moderate-to-severe dementia, Parkinson's disease, recent rejection, dual organ transplants, severe kidney or liver dysfunction, active cancer, uncontrolled psychiatric illness, pregnancy, or other listed exclusions are unlikely to benefit or are not eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, controlled, single-center trial at Massachusetts General Hospital compares continuing immediate-release tacrolimus with conversion to an extended-release formulation (Envarsus XR) in older kidney transplant recipients who are at least one year post-transplant and have stable tacrolimus levels. Participants are randomized to either maintain their current immediate-release regimen or be converted to the extended-release product, with neurocognitive testing performed at baseline and follow-up to measure changes in cognition and related symptoms. The trial enrolls patients who receive routine follow-up at the MGH transplant clinic and who speak English or Spanish. Safety monitoring includes routine graft function and tacrolimus trough level checks during the maintenance period.

Why it matters

Potential benefit: If successful, switching to extended-release tacrolimus could reduce neurotoxic side effects and lead to better cognitive function and quality of life for older transplant recipients.

How similar studies have gone: Some prior work indicates extended-release tacrolimus can lower peak-related side effects such as tremor, but direct evidence showing cognitive improvement in older kidney transplant recipients is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Able to give informed consent for participation in the study
* Patients who have regular outpatient follow-up at the Massachusetts General Hospital (MGH) transplant center
* ≥1 year since the latest kidney transplantation
* On IR tacrolimus as maintenance therapy
* At a stable therapeutic tacrolimus level (5-10 ng/ml) over the last ≥3 months
* Stable kidney function \[\<20% variability between the last two estimated glomerular filtration rate (eGFR)\]
* Utilizing English or Spanish as the primary language

Exclusion Criteria:

* Dual organ transplantation
* Rejection within the last three months
* History of moderate to severe dementia (defined by Dementia Severity Rating Scale ≥19)
* History of Parkinson's disease
* Decompensated liver disease
* Active cancer
* Uncontrolled depression or anxiety
* Blindness
* Deafness
* Intellectual disabilities
* Pregnancy
* eGFR \<15 mL/min/1.73 m2 at the time of enrollment
* Total bilirubin \>3.0 mg/dL

Where it's running

  • MGH Kidney Transplant Clinic
    Boston, Massachusetts, United States
    Recruiting

Study contacts

  • Principal investigator: Leonardo V. Riella, MD, PhD — Massachusetts General Hospital
  • Study coordinator: Leonardo V. Riella, MD, PhD
  • Email: lriella@mgh.harvard.edu
  • Phone: 6177240345

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.